Treatment evaluation in benign prostatic hyperplasia (BPH) is complicated by a number of interdependent factors. The evaluation of the individual patient is influenced by the riskibenefit ratio and health related quality of life and this,in turn, is interrelated with the evaluation of therapeutic options. Current outcome measures include subjective measurements (e.g. symptom scores and patient reports) and objective measurements (e.g. uroflow and prostate volume). In order to improve outcome measures it is important to use healthrelated quality-of-life scales and symptom- and bother-associated scores. In addition, the patient should complete frequency and volume charts, and possibly use home flowmetry; transitional zone measurements may also play a role in finding a better treatment strategy. It is also important to consider the adverse effects and complication rates of invasive and pharmacological treatments(including their influence on quality of life) and economic factors such as the cost of treatment, the cost of following guidelines and the durability and failure rate associated with treatment. In order to manage the increasing number of BPH patients who seek care effectively it is important to share care with the GPs, but this will require improved guidelines, better data and better outcome measurements.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.